Correlation Between Oracle and Dermata Therapeutics

Can any of the company-specific risk be diversified away by investing in both Oracle and Dermata Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oracle and Dermata Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oracle and Dermata Therapeutics Warrant, you can compare the effects of market volatilities on Oracle and Dermata Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oracle with a short position of Dermata Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oracle and Dermata Therapeutics.

Diversification Opportunities for Oracle and Dermata Therapeutics

-0.04

Correlation Coefficient

Oracle  Dermata Therapeutics

Good diversification

The 3 months correlation between Oracle and Dermata is -0.04. Overlapping area represents the amount of risk that can be diversified away by holding Oracle and Dermata Therapeutics Warrant in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dermata Therapeutics and Oracle is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oracle are associated (or correlated) with Dermata Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dermata Therapeutics has no effect on the direction of Oracle i.e., Oracle and Dermata Therapeutics go up and down completely randomly.

Pair Corralation between Oracle and Dermata Therapeutics

Given the investment horizon of 90 days Oracle is expected to under-perform the Dermata Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Oracle is 7.19 times less risky than Dermata Therapeutics. The stock trades about -0.05 of its potential returns per unit of risk. The Dermata Therapeutics Warrant is currently generating about 0.19 of returns per unit of risk over similar time horizon. If you would invest  1.07  in Dermata Therapeutics Warrant on December 29, 2024 and sell it today you would earn a total of  1.73  from holding Dermata Therapeutics Warrant or generate 161.68% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	78.69%
Values	Daily Returns

Oracle  vs.  Dermata Therapeutics Warrant

Oracle

Risk-Adjusted Performance

Very Weak

Over the last 90 days Oracle has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest abnormal performance, the Stock's fundamental indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors.

Dermata Therapeutics

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Dermata Therapeutics Warrant are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Dermata Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Oracle and Dermata Therapeutics

The main advantage of trading using opposite Oracle and Dermata Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oracle position performs unexpectedly, Dermata Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will offset losses from the drop in Dermata Therapeutics' long position.

The idea behind Oracle and Dermata Therapeutics Warrant pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.